Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P.

J Immunother Cancer. 2019 Feb 13;7(1):46. doi: 10.1186/s40425-019-0519-y.

2.

A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers.

Baverel P, She D, Piper E, Ueda S, Yoshioka T, Faggioni R, Gevorkyan H.

Drug Metab Pharmacokinet. 2018 Jun;33(3):150-158. doi: 10.1016/j.dmpk.2017.12.001. Epub 2017 Dec 12.

3.

Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspring.

Nicholson SM, Carlesso G, Cheng LI, Cook H, DaCosta K, Leininger J, McKeever K, Scott SW, Taylor D, Streicher K, Eck S, Reed M, Faggioni R, Herbst R, Dixit R, Ryan PC.

Reprod Toxicol. 2017 Dec;74:116-133. doi: 10.1016/j.reprotox.2017.08.018. Epub 2017 Sep 13.

PMID:
28916434
4.

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.

Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, Higgins PDR, Newbold P, Faggioni R, Patra K, Li J, Klekotka P, Morehouse C, Pulkstenis E, Drappa J, van der Merwe R, Gasser RA Jr.

Gastroenterology. 2017 Jul;153(1):77-86.e6. doi: 10.1053/j.gastro.2017.03.049. Epub 2017 Apr 5.

5.

Cytokine release assays: current practices and future directions.

Finco D, Grimaldi C, Fort M, Walker M, Kiessling A, Wolf B, Salcedo T, Faggioni R, Schneider A, Ibraghimov A, Scesney S, Serna D, Prell R, Stebbings R, Narayanan PK.

Cytokine. 2014 Apr;66(2):143-55. doi: 10.1016/j.cyto.2013.12.009. Epub 2014 Jan 10. Review.

PMID:
24412476
6.

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.

Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y.

Pharmacol Ther. 2014 Feb;141(2):125-39. doi: 10.1016/j.pharmthera.2013.09.004. Epub 2013 Sep 27. Review.

PMID:
24076269
7.

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma.

Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP, Molfino NA.

Eur Respir J. 2013 Feb;41(2):330-8. doi: 10.1183/09031936.00223411. Epub 2012 Jun 27.

8.

Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics.

Finch DK, Sleeman MA, Moisan J, Ferraro F, Botterell S, Campbell J, Cochrane D, Cruwys S, England E, Lane S, Rendall E, Sinha M, Walker C, Rees G, Bowen MA, Schneider A, Liang M, Faggioni R, Fung M, Mallinder PR, Wilkinson T, Kolbeck R, Vaughan T, Lowe DC.

J Mol Biol. 2011 Aug 26;411(4):791-807. doi: 10.1016/j.jmb.2011.06.031. Epub 2011 Jun 23.

PMID:
21723291
9.

PK-PD modeling of protein drugs: implications in assay development.

Roskos LK, Schneider A, Vainshtein I, Schwickart M, Lee R, Lu H, Faggioni R, Liang M.

Bioanalysis. 2011 Mar;3(6):659-75. doi: 10.4155/bio.11.28. Review.

PMID:
21417734
10.

An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males.

Oh CK, Faggioni R, Jin F, Roskos LK, Wang B, Birrell C, Wilson R, Molfino NA.

Br J Clin Pharmacol. 2010 Jun;69(6):645-55. doi: 10.1111/j.1365-2125.2010.03647.x.

11.

A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma.

Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A.

BMC Pulm Med. 2010 Jan 8;10:3. doi: 10.1186/1471-2466-10-3.

12.

Spontaneous rupture of posterior capsule.

de Courten C, Faggioni R.

J Cataract Refract Surg. 2008 Feb;34(2):179-80; author reply 180. doi: 10.1016/j.jcrs.2007.09.032. No abstract available.

PMID:
18242422
14.

Regulatory effects of osteoprotegerin on cellular and humoral immune responses.

Stolina M, Guo J, Faggioni R, Brown H, Senaldi G.

Clin Immunol. 2003 Dec;109(3):347-54.

PMID:
14697750
15.

Regulatory effects of novel neurotrophin-1/b cell-stimulating factor-3 (cardiotrophin-like cytokine) on B cell function.

Senaldi G, Stolina M, Guo J, Faggioni R, McCabe S, Kaufman SA, Van G, Xu W, Fletcher FA, Boone T, Chang MS, Sarmiento U, Cattley RC.

J Immunol. 2002 Jun 1;168(11):5690-8.

16.

Leptin deficiency, not obesity, protects mice from Con A-induced hepatitis.

Siegmund B, Lear-Kaul KC, Faggioni R, Fantuzzi G.

Eur J Immunol. 2002 Feb;32(2):552-60.

17.

Leptin regulation of the immune response and the immunodeficiency of malnutrition.

Faggioni R, Feingold KR, Grunfeld C.

FASEB J. 2001 Dec;15(14):2565-71. Review.

PMID:
11726531
18.

IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice.

Faggioni R, Cattley RC, Guo J, Flores S, Brown H, Qi M, Yin S, Hill D, Scully S, Chen C, Brankow D, Lewis J, Baikalov C, Yamane H, Meng T, Martin F, Hu S, Boone T, Senaldi G.

J Immunol. 2001 Nov 15;167(10):5913-20.

19.

WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection.

Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, Mu S, Xia M, Wakeham AC, Nishina H, Potter J, Saris CJ, Mak TW.

Immunity. 2001 Oct;15(4):569-78.

20.

Leptin in the regulation of immunity, inflammation, and hematopoiesis.

Fantuzzi G, Faggioni R.

J Leukoc Biol. 2000 Oct;68(4):437-46. Review.

PMID:
11037963
21.

Reduced leptin levels in starvation increase susceptibility to endotoxic shock.

Faggioni R, Moser A, Feingold KR, Grunfeld C.

Am J Pathol. 2000 May;156(5):1781-7.

22.

Upregulation of uncoupling protein 2 mRNA in genetic obesity: lack of an essential role for leptin, hyperphagia, increased tissue lipid content, and TNF-alpha.

Memon RA, Hotamisligil GS, Wiesbrock SM, Uysal KT, Faggioni R, Moser AH, Feingold KR, Grunfeld C.

Biochim Biophys Acta. 2000 Feb 24;1484(1):41-50.

PMID:
10685029
23.

Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18.

Faggioni R, Jones-Carson J, Reed DA, Dinarello CA, Feingold KR, Grunfeld C, Fantuzzi G.

Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2367-72.

24.

Comparison of deep sclerectomy with collagen implant and trabeculectomy in open-angle glaucoma.

Mermoud A, Schnyder CC, Sickenberg M, Chiou AG, H├ędiguer SE, Faggioni R.

J Cataract Refract Surg. 1999 Mar;25(3):323-31.

PMID:
10079436
25.

Leptin deficiency enhances sensitivity to endotoxin-induced lethality.

Faggioni R, Fantuzzi G, Gabay C, Moser A, Dinarello CA, Feingold KR, Grunfeld C.

Am J Physiol. 1999 Jan;276(1):R136-42. doi: 10.1152/ajpregu.1999.276.1.R136.

PMID:
9887187
26.

Recently identified peptides involved in the regulation of body weight.

Bessesen DH, Faggioni R.

Semin Oncol. 1998 Apr;25(2 Suppl 6):28-32. Review.

PMID:
9625380
27.

Induction of UCP2 gene expression by LPS: a potential mechanism for increased thermogenesis during infection.

Faggioni R, Shigenaga J, Moser A, Feingold KR, Grunfeld C.

Biochem Biophys Res Commun. 1998 Mar 6;244(1):75-8.

PMID:
9514886
28.

IL-1 beta mediates leptin induction during inflammation.

Faggioni R, Fantuzzi G, Fuller J, Dinarello CA, Feingold KR, Grunfeld C.

Am J Physiol. 1998 Jan;274(1):R204-8. doi: 10.1152/ajpregu.1998.274.1.R204.

PMID:
9458919
29.

LPS-induced anorexia in leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice.

Faggioni R, Fuller J, Moser A, Feingold KR, Grunfeld C.

Am J Physiol. 1997 Jul;273(1 Pt 2):R181-6.

PMID:
9249548
30.

Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.

Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A.

Immunity. 1997 Mar;6(3):315-25.

31.

Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumour necrosis factor.

Romano M, Faggioni R, Sironi M, Sacco S, Echtenacher B, Di Santo E, Salmona M, Ghezzi P.

Mediators Inflamm. 1997;6(1):32-8.

32.

TNF receptor p55 plays a major role in centrally mediated increases of serum IL-6 and corticosterone after intracerebroventricular injection of TNF.

Benigni F, Faggioni R, Sironi M, Fantuzzi G, Vandenabeele P, Takahashi N, Sacco S, Fiers W, Buurman WA, Ghezzi P.

J Immunol. 1996 Dec 15;157(12):5563-8.

PMID:
8955207
33.

Effect of endotoxin in IL-1 beta-deficient mice.

Fantuzzi G, Zheng H, Faggioni R, Benigni F, Ghezzi P, Sipe JD, Shaw AR, Dinarello CA.

J Immunol. 1996 Jul 1;157(1):291-6.

PMID:
8683129
34.

Ultrasound biomicroscopy of eyes undergoing deep sclerectomy with collagen implant.

Chiou AG, Mermoud A, H├ędiguer SE, Schnyder CC, Faggioni R.

Br J Ophthalmol. 1996 Jun;80(6):541-4.

35.

Delineation of a 1-cM region on distal 5q containing the locus for corneal dystrophies Groenouw type I and lattice type I and exclusion of the candidate genes SPARC and LOX.

Korvatska E, Munier FL, Zografos L, Ahmad F, Faggioni R, Dolivo-Beuret A, Uffer S, Pescia G, Schorderet DF.

Eur J Hum Genet. 1996;4(4):214-8.

PMID:
8875187
36.

[Comparative study of administration time of mitomycin C in trabeculectomy: 2.5 or 5 minutes?].

Schnyder CC, Bernasconi O, Mermoud A, Faggioni R.

Klin Monbl Augenheilkd. 1995 May;206(5):307-11. French.

PMID:
7609372
37.

Independent down-regulation of central and peripheral tumor necrosis factor production as a result of lipopolysaccharide tolerance in mice.

Faggioni R, Fantuzzi G, Villa P, Buurman W, van Tits LJ, Ghezzi P.

Infect Immun. 1995 Apr;63(4):1473-7.

38.

Mechanisms of interleukin-2-induced depression of hepatic cytochrome P-450 in mice.

Cantoni L, Carelli M, Ghezzi P, Delgado R, Faggioni R, Rizzardini M.

Eur J Pharmacol. 1995 Mar 16;292(3-4):257-63.

PMID:
7796864
39.

Proinflammatory cytokines as pathogenetic mediators in the central nervous system: brain-periphery connections.

Faggioni R, Benigni F, Ghezzi P.

Neuroimmunomodulation. 1995 Jan-Feb;2(1):2-15. Review.

PMID:
7614256
40.

Defective inflammatory response in interleukin 6-deficient mice.

Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V.

J Exp Med. 1994 Oct 1;180(4):1243-50.

41.

Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice.

Mengozzi M, Fantuzzi G, Faggioni R, Marchant A, Goldman M, Orencole S, Clark BD, Sironi M, Benigni F, Ghezzi P.

Immunology. 1994 Jun;82(2):207-10.

42.

[Re-evaluation of the role of argon laser trabeculoplasty in therapy of glaucoma].

Altamirano D, Schnyder C, Faggioni R, Guex-Crosier Y, Herbort CP.

Klin Monbl Augenheilkd. 1994 May;204(5):292-4. French.

PMID:
8051854
43.

Mechanisms of interleukin-2-induced hydrothoraxy in mice: protective effect of endotoxin tolerance and dexamethasone and possible role of reactive oxygen intermediates.

Faggioni R, Allavena P, Cantoni L, Carelli M, Demitri MT, Delgado R, Gatti S, Gnocchi P, Isetta AM, Paganin C, et al.

J Immunother Emphasis Tumor Immunol. 1994 Apr;15(3):194-201.

PMID:
8032542
44.

Role of xanthine oxidase and reactive oxygen intermediates in LPS- and TNF-induced pulmonary edema.

Faggioni R, Gatti S, Demitri MT, Delgado R, Echtenacher B, Gnocchi P, Heremans H, Ghezzi P.

J Lab Clin Med. 1994 Mar;123(3):394-9.

PMID:
8133151
45.

Mast cells do not contribute to the rapid appearance of TNF in the serum of LPS-treated mice: a study with mast cell-deficient mice.

Gatti S, Faggioni R, Sironi M, Erroi A, Ghezzi P.

Int J Immunopharmacol. 1993 Jul;15(5):551-5.

PMID:
8375937
46.
47.

Molecular mapping and detoxification of the lipid A binding site by synthetic peptides.

Rustici A, Velucchi M, Faggioni R, Sironi M, Ghezzi P, Quataert S, Green B, Porro M.

Science. 1993 Jan 15;259(5093):361-5.

PMID:
8420003
48.

Urinary TNF-binding protein (TNF soluble receptor) protects mice against the lethal effect of TNF and endotoxic shock.

Bertini R, Delgado R, Faggioni R, Gascon MP, Ythier A, Ghezzi P.

Eur Cytokine Netw. 1993 Jan-Feb;4(1):39-42.

PMID:
8387827
49.

[Effect of naftidrofuryl (Praxilene) in primary open angle glaucoma: prospective double-blind study].

Beati D, Mermoud A, Faggioni R.

Klin Monbl Augenheilkd. 1992 May;200(5):407-8. French.

PMID:
1614112
50.

[Long-term results of congenital glaucoma microsurgery--retrospective study].

de Ancos E, Faggioni R, de Courten C.

Klin Monbl Augenheilkd. 1992 May;200(5):398-400. French.

PMID:
1614110

Supplemental Content

Loading ...
Support Center